As booster shots become increasingly available and COVID-19 vaccines for young children are introduced into pediatric offices, several potential therapeutics to battle the SARS-CoV-2 virus are lining up for regulatory authorizations.
On target with last year, a total of 87% of funds recorded in 2021 through biopharma collaborations with nonprofit entities by the end of October are focused on COVID-19 pandemic efforts. The pandemic accounts for 54% of the money collected through grants, which is still a sturdy amount but down from 76% in 2020.
Marking September as the second busiest month, 2021 is more than 6% ahead of last year in terms of reported clinical data, although the gap between the two years has narrowed significantly from 26% in April.
RSS
